An official website of the United States government
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Trial Status: active
This is a multicenter clinical trial to evaluate the safety and preliminary activity of
the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy
in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and
castration-resistant prostate cancer.
Inclusion Criteria
Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Able to take oral medication
If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
Adequate organ function and electrolytes Key
Exclusion Criteria
Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
Impaired cardiac function
Major surgery within 28 days of the first dose of study drug
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06966024.
